- Home
- THRM vs XERS Comparison
THRM vs XERS Comparison
Compare THRM & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THRM | XERS |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | THRM | XERS |
|---|---|---|
| Price | $39.62 | $8.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $37.20 | $10.83 |
| AVG Volume (30 Days) | 274.4K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $554,979,000.00 | $49,590,000.00 |
| Revenue This Year | $4.96 | $34.37 |
| Revenue Next Year | $7.12 | $22.86 |
| P/E Ratio | $141.00 | ★ N/A |
| Revenue Growth | 50.16 | ★ 142.67 |
| 52 Week Low | $27.00 | $5.25 |
| 52 Week High | $48.35 | $10.08 |
Technical Indicators
Market Signals| Indicator | THRM | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 53.83 |
| Support Level | $40.07 | $8.00 |
| Resistance Level | $44.45 | $9.01 |
| Average True Range (ATR) | 1.26 | 0.28 |
| MACD | -0.34 | -0.03 |
| Stochastic Oscillator | 29.53 | 40.47 |
Price Performance
Historical ComparisonAbout THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.